Dupilumab After JAK Inhibitor Withdrawal: Small Real-World Signal
This single-center case series offers preliminary real-world guidance on transitioning moderate-to-severe atopic dermatitis patients from Janus kinase inhibitors to dupilumab, with attention to early relapse during immediate switching.
Switching from JAK inhibitors to dupilumab shows promise in atopic dermatitis management.
Switching treatments in atopic dermatitis (AD) can be challenging, and understanding alternatives like dupilumab after janus kinase inhibitor (JAKi) discontinuation is important for patient management. Within 16 weeks of switching to dupilumab, 93.33% of patients showed clinical improvement, with no adverse events reported compared to 46.67% with JAKi. This study suggests dupilumab as a feasible option post-JAKi for AD, although disease fluctuations are possible, indicating the need for further research. Dupilumab may effectively manage moderate-to-severe AD after JAKi discontinuation, though patient monitoring for disease fluctuations is important.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Wang Q, Yang G, Li Y, Xue J, Zhang L
Citation:Wang Q, Yang G, Li Y, et al. Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center retrospective study. Frontiers in immunology. 2026;17:1841762. doi:10.3389/fimmu.2026.1841762